ISAB's contract research organization Inhalation Research Services (IRS), has signed a new contract worth
The current client is a developer of new small molecule treatments for a wide range of respiratory diseases including asthma and COPD. The company has chosen to run dissolution tests on a new substance using ISAB's leading in vitro lung simulation tool DissolvIt®.
DissolvIt® has been increasingly recognized in the inhalation industry as a leading solution for generating "IVIVC" data - that is in vitro dissolution and absorption data early on in the drug development process that closely predicts later-stage in vivo data. Such data can significantly reduce risk and costs early on in drug development.
With a growing body of publications like "In Vitro to ex
ISAB CEO Manoush Masarrat: "We are very pleased to be working with this new US client. This clearly demonstrates the client's confidence in our world-class expertise, and the leading in vitro capabilities of DissolvIt®. We are delighted to carry out this research and look forward to this exciting collaboration."
Explore DissolvIt's extensive in vitro capabilities here.
Read ISAB's publications on DissolvIt®here.
For more information about Inhalation Sciences, please contact:
Manoush Masarrat, CEO
E-mail: Manoush.masarrat@inhalation.se
Mobile: +46 (0)73 628 9153
About
The information above was provided by
https://news.cision.com/inhalation-sciences/r/inhalation-sciences-signs-irs-contract-worth-1-39-million-sek-with-new-us-respiratory-pharma-client,c3631503
https://mb.cision.com/Main/15842/3631503/1627132.pdf
(c) 2022 Cision. All rights reserved., source